Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Candel Therapeutics, Inc. (CADL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Candel is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market under the symbol CADL, as noted in multiple Form 8-K filings. Its filings document material events related to its multimodal viral immunotherapy programs, capital structure, and key agreements.
Investors can review current reports on Form 8-K describing clinical and corporate milestones, such as interim data from the phase 1b trial of CAN-3110 in recurrent glioblastoma, progress with CAN-2409 in localized prostate cancer, NSCLC, and PDAC, and strategic decisions to prioritize certain indications. Other 8-K filings outline financing arrangements, including a Loan and Security Agreement with Trinity Capital Inc. for up to $130 million in term loans, registered direct equity offerings under an effective shelf registration statement, warrant amendments, and lease extensions for facilities in Needham, Massachusetts.
These filings also identify when Candel issues press releases on quarterly financial results, R&D events, and material agreements, and they confirm that CADL common stock is registered under Section 12(b) of the Exchange Act. By examining items such as Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, and Regulation FD Disclosure, users can understand how Candel reports on its financial position, capital resources, and clinical program updates.
On Stock Titan, AI-powered tools can help summarize lengthy Candel filings, highlight key sections, and surface references to topics like CAN-2409, CAN-3110, the enLIGHTEN™ Discovery Platform, and regulatory designations. This allows readers to quickly identify information on term loan covenants, equity offerings, and clinical data disclosures without manually parsing each document.
Insider Trading Alert: Joseph C. Papa, Director of Candel Therapeutics (NASDAQ: CADL), acquired 64,239 shares of common stock on June 25, 2025, through a registered direct offering at $4.67 per share. The transaction was executed through the Joseph C. Papa Revocable Living Trust.
Key Transaction Details:
- Total shares acquired: 64,239 shares
- Purchase price: $4.67 per share
- Transaction value: approximately $300,000
- Post-transaction holdings: 64,239 shares (indirect) + 38,032 shares (direct)
The acquisition was made pursuant to a Securities Purchase Agreement dated June 23, 2025. The shares are held indirectly through a trust arrangement, with Papa serving as trustee. This insider purchase may signal management's confidence in the company's prospects.
Candel Therapeutics, Inc. (CADL) – Form 4 filing dated 06/24/2025
The company’s Chief Financial Officer, Charles Schoch, reported the grant of a stock option for 50,000 shares of common stock with an exercise price of $4.75 per share. The option was issued on 06/20/2025 and will expire on 06/20/2035.
Vesting schedule: 25 % of the award vests on 06/20/2026; the remaining 75 % vests in 36 equal monthly installments thereafter, contingent on continued service.
Following this transaction, Mr. Schoch beneficially owns 50,000 derivative securities (stock options) directly. No open-market purchases or sales of CADL common shares were disclosed.
Candel Therapeutics has announced a registered direct offering of 3,221,395 shares of common stock at $4.67 per share, expected to raise approximately $15.0 million in gross proceeds. The offering price equals the closing price reported on Nasdaq Global Market on June 23, 2025.
Key details of the offering include:
- Purchasers include existing healthcare-focused institutional investors, executive officers, and directors
- Offering is made under shelf registration statement (File No. 333-266605) declared effective August 12, 2022
- Closing anticipated for June 25, 2025, subject to customary conditions
The company, an emerging growth company, is conducting this offering to strengthen its financial position. The securities purchase agreement was signed on June 23, 2025, with shares being offered through a registered direct offering structure. This strategic financing move involves both institutional and insider participation, potentially signaling management's confidence in the company's prospects.